Yasser Medhat Kamel

Yasser Medhat Kamel

Auto-generated profile, based on publicly available information

Yasser Medhat Kamel

Department of Gastroenterology, Ambulatory Care Center, Hamad Medical Corporation, Doha, Qatar, hamad.qa

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
KMKamran Mushtaq
Kamran Mushtaq
MKMuhammad Umair Khan
Muhammad Umair Khan
FIFatima Iqbal
Fatima Iqbal
DADeema Hussam Alsoub
Deema Hussam Alsoub
HCHammad Shabir Chaudhry
Hammad Shabir Chaudhry
YKYasser Medhat Kamel
Yasser Medhat Kamel

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MDMoutaz Derbala
Moutaz Derbala
MEMohammed Elshiekh Elbadri
Mohammed Elshiekh Elbadri
AAAliaa Mohamed Amer
Aliaa Mohamed Amer
SASaad AlKaabi
Saad AlKaabi
KSKhaleel Hassan Sultan
Khaleel Hassan Sultan
FSFatma M Shebl
Fatma M Shebl
AIM: To assess the diagnostic accuracy, of aminotransferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection. METHODS: This retrospective study included medical records of three hundred and eighty three Egyptian men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present. RESULTS: Median age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage. CONCLUSION: The study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.

1 January 2025 in Case Reports in Hepatology
Verified
Journal Article
Open access
GKGi Eun Kim
Gi Eun Kim
MIMariam Imran
Mariam Imran
SMSherif Mostafa
Sherif Mostafa
YKYasser Kamel
Yasser Kamel
Primary biliary cholangitis is a progressive disease with complications such as liver cirrhosis and hepatocellular carcinoma, and the treatment goal is to delay its progression. One of the markers for treatment response is alkaline phosphatase levels. Baricitinib has been used in one randomized controlled trial involving two patients to improve outcomes in unresponsive primary biliary cholangitis. We present a case of primary biliary cholangitis who had incomplete response to ursodeoxycholic acid, obeticholic acid, and fenofibrate but showed complete response to baricitinib in terms of sustained normalized alkaline phosphatase levels.

19 June 2022 in Gut
Verified
Conference Paper
Closed access
PDF file
MKMuhammad Khan
Muhammad Khan
KMKamran Mushtaq
Kamran Mushtaq
DADeema AlSoub
Deema AlSoub
Muhammad Nabeel SaddiqueMuhammad Nabeel Saddique
Muhammad Nabeel Saddique
STShahrad Taheri
Shahrad Taheri
YKYasser Kamel
Yasser Kamel
Introduction COVID-19 patients with abnormal liver tests, especially ALT and AST, are at higher risk of progressing to severe disease. There is a discrepancy between gamma glutamyl transferase (GGT) and alkaline phosphatase elevation (ALP) in COVID-19 patients. We hypothesized that elevated GGT at admission in COVID-19 patients is independently associated with disease severity and adverse outcomes. Methods We studied 232 patients with confirmed symptomatic COVID-19 who were consecutively hospitalized in the first half of March 2021 in our hospital in Qatar. We categorized them into three groups; borderline if GGT was normal or less than twice the upper limit of normal (ULN), mild if elevated 2-5 times, and moderate if more than five times the ULN. The primary outcome was mortality, and secondary outcomes were disease severity on presentation and intensive Care Unit (ICU) admission. The Medical Research Centre of Hamad Medical Corporation approved the study. Results Patients with moderate GGT elevation were not different in age, BMI, gender distribution, Charlson comorbid index, transaminase levels, albumin, and bilirubin levels but had elevated ferritin and LDH levels. For ALP levels, 75% of the patients had normal levels, 18% had borderline elevation (less than twice the ULN), and the remaining had mild elevation (2x -5x). In univariate analysis, COVID-19 patients with moderate GGT elevation had higher mortality (p = 0.006) and more severe disease at presentation (p=0.003), but no statically increased risk of ICU admission and requirement of mechanical ventilation. In multivariate regression analysis, patients with moderate GGT elevation remained at increased risk of mortality odds ratio (OR) 3.09 (C.I. 1.1-9.67 p = 0.04) and severe disease at presentation OR 1.57 (C.I.1.2 – 2.65 p=0.048). Conclusions In COVID-19 patients, the moderate elevation of GGT at presentation is an independent predictor of disease severity and increased mortality. Elevated GGT levels are a marker of disease severity rather than cholestasis in COVID-19 patients.